The mAbelotuzumab, which enhances natural killer (NK) cell-mediated cytotoxicity, has been FDA-approved for MM treatment, underscoring the clinical relevance of CS1 targeting [124]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.